Melanocortins and sexual function: desire in the brain, not the bloodstream

One signal followed past hunger into desire — the same receptor, read in a different room of the brain, doing a job no one went looking for.

The melanocortin system is best known for pigment, the stress axis, appetite, and inflammation. Sexual function is its quietest and most surprising reach — and it arrives by the same route as everything else the system does in the head: through MC4R, the appetite receptor, acting centrally in the brain.^[1] The remarkable part is not that a melanocortin drug can improve the mechanics of sex. It is that one can lift desire itself.

Desire is upstream of plumbing

The cleanest way to understand melanocortin sexual pharmacology is to separate two things that everyday language runs together: the wanting and themechanics. PDE5 inhibitors — Viagra and its relatives — work on the mechanics. They act in the periphery, improving blood flow in the genitals, and they do so only once arousal is already present; they carry out an order the brain has already given. A melanocortin agonist works at the other end. It acts centrally, on the circuits that generate desire and arousal in the first place, so it can start the signal rather than merely execute it.^[1][3]

Found, not designed

No one set out to build a desire drug from the melanocortin system. The branch opened by accident. In trials of Melanotan II, the peptide being pushed as a sunless tan, researchers kept noting a striking and consistent side effect: spontaneous sexual arousal. Rather than discard it, chemists re-worked the molecule to strip out most of the pigment activity while keeping the pro-sexual effect — and the result became PT-141 / bremelanotide.^[1]It is the same lineage that produced the approved tanning drug afamelanotide; where afamelanotide is the pigment side of the melanotan story made into medicine, bremelanotide is the other side effect made into one. For how tangled that family tree gets, see PT-141 vs Melanotan.

What the evidence actually shows

The central effect is not just a mechanistic story; it has been tested in both sexes. In men, an intranasal melanocortin agonist produced erections in healthy volunteers and in patients with mild-to-moderate erectile dysfunction, acting through the brain rather than the bloodstream — a different route from the PDE5 inhibitors, and one that worked in some men they did not.^[2] In women, the pivotal RECONNECT trials tested bremelanotide for acquired, generalised hypoactive sexual desire disorder (HSDD) — a persistent, distressing lack of sexual desire — and showed improvements in desire and in the distress it causes.^[4] On that basis the FDA approved it in 2019, the first on-demand treatment for HSDD in premenopausal women.^[3]

The two stories end differently, and that difference is itself informative. The programme in men was not carried to approval: an earlier intranasal route raised blood pressure enough to halt it, and development refocused on women with a subcutaneous dose.^[1] So the one approved melanocortin sexual-function drug treats desire in women, while the effect in men — real in early trials — remains off-label and unapproved.

The honest limits

This is a genuine effect, but a bounded one. Bremelanotide is approved for a specific diagnosis in a specific population, not as a general libido enhancer, and its tolerability is real: nausea is common, and because it transiently raises blood pressure it is contraindicated in uncontrolled hypertension and known cardiovascular disease.^[3] The grey-market “PT-141” sold as vials and nasal sprays is the unapproved version of the same molecule, of unknown purity and dose — the sexual-function counterpart to the melanotan tanning peptides, and carrying the same caution. The science here is sound and specific; the marketing around it usually is not.

The honest bottom line

Sexual function is the melanocortin system doing, one more time, the thing this whole site keeps finding: reaching into a place no one expected, through a receptor it was already using for something else. The appetite switch turned out to sit in the circuitry of desire, and a tanning peptide's side effect turned out to be a drug. For the molecule, see bremelanotide (PT-141); for the receptor it works through, see MC4R — the appetite rheostat; for the lineage it came from, see Melanotan.